Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
Department of Cardiology, Copenhagen University Hospital, Hvidovre, Denmark.
PLoS One. 2022 Jun 28;17(6):e0270603. doi: 10.1371/journal.pone.0270603. eCollection 2022.
Patients with cirrhosis and portal hypertension are at high risk of developing complications such as variceal hemorrhage, ascites, and cardiac dysfunction, the latter of which is known as cirrhotic cardiomyopathy. Since non-selective beta-blockers (NSBB) may aggravate hemodynamic complications we investigated the effect of real-time propranolol infusion on cardiac function in patients with varying degrees of cirrhosis.
Thirty-eight patients with Child-Pugh A (n = 17), B (n = 17) and C (n = 4) underwent liver vein catheterization and cardiac magnetic resonance imaging. We assessed the effect of real-time propranolol infusion on the hepatic venous pressure gradient, cardiac index, stroke volume, ejection fraction, heart rate, and contractility.
Nineteen patients were classified as responders to beta-blocker therapy. In pooling Child-Pugh B and C patients, the reduction in cardiac index by beta-blockade was weaker than in Child-Pugh A patients (-8.5% vs. -20.5%, p = 0.043). The effect of NSBB on portal pressure was inversely correlated to changes in the left atrium where the left atrial volume changed by 4 mL±18 in responders compared to 15 mL±11 in non-responders (p = 0.03). Finally, the baseline ejection fraction correlated inversely with the reduction in portal pressure (r = -0.39, p = 0.02).
We found the effect of beta-blockade on cardiac index in patients with advanced cirrhosis to be less potent than in patients with early cirrhosis, indicating that underlying cirrhotic cardiomyopathy increases, and the cardiac compensatory reserve becomes more compromised, with disease progression. The differential effects of beta-blockade in the left atrium may be used to predict the effect of beta-blockers on portal pressure, but further studies are needed to investigate this possibility.
肝硬化和门静脉高压症患者发生静脉曲张出血、腹水和心功能障碍等并发症的风险较高,后者被称为肝硬化性心肌病。由于非选择性β受体阻滞剂(NSBB)可能加重血流动力学并发症,我们研究了实时普萘洛尔输注对不同程度肝硬化患者心功能的影响。
38 名 Child-Pugh A 级(n=17)、B 级(n=17)和 C 级(n=4)患者进行肝静脉导管插入术和心脏磁共振成像。我们评估了实时普萘洛尔输注对肝静脉压力梯度、心指数、心排量、射血分数、心率和收缩力的影响。
19 名患者被归类为β受体阻滞剂治疗的反应者。在汇集 Child-Pugh B 和 C 级患者中,β受体阻滞剂对心指数的降低作用弱于 Child-Pugh A 级患者(-8.5%对-20.5%,p=0.043)。NSBB 对门静脉压力的影响与左心房的变化呈反比,反应者的左心房容积变化为 4 毫升±18,而非反应者为 15 毫升±11(p=0.03)。最后,基线射血分数与门静脉压力降低呈反比(r=-0.39,p=0.02)。
我们发现,晚期肝硬化患者β受体阻滞剂对心指数的影响不如早期肝硬化患者强,这表明潜在的肝硬化性心肌病增加,心脏代偿储备随着疾病进展而变得更加受损。β受体阻滞剂在左心房的不同作用可能用于预测β受体阻滞剂对门静脉压力的影响,但需要进一步研究来探讨这种可能性。